The patients with low baseline CgA levels had significantly better OS in pancreatic NETs (survival rate 96.6% vs 57.1%, P=0.0002) but not in non-pancreatic NETs (survival rate 100% vs 87.9%, P=0.317). The gene discussed is CGA; the disease is pancreatic neuroendocrine tumor.